We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Yourgene Health Plc | LSE:YGEN | London | Ordinary Share | GB00BN31ZD89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.515 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMYGEN
RNS Number : 1841L
Yourgene Health PLC
12 May 2022
Yourgene Health plc
("Yourgene" or the "Company")
CEO share purchase
Director/PDMR Shareholding
Manchester, UK - 12 May 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified 11 May 2022 that Lyn Rees, Chief Executive Officer of the Company, purchased 1,000,000 (1 million) ordinary shares on 11 May 2022 at a price of 7p per share in his SIPP account.
Following the above transaction, Lyn Rees is interested in 2,037,902 ordinary shares in the Company, representing approximately 0.3 per cent. of the Company's issued share capital.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122 Lyn Rees, Chief Executive Officer investors@yourgene-health.com Barry Hextall, Chief Financial Officer Joanne Cross, Director of Marketing Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880 Liam Murray / James Caithie / Ludovico Lazzaretti Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000 Broker) Aubrey Powell / Tom Salvesen / George Tzimas Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600 Corporate Broker) Nicholas Moore / Matthew Blawat / Ben Maddison Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com Relations) Paul McManus / Lianne Applegarth Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Details of the person discharging managerial responsibilities 1 / person closely associated a) Name Lyn Rees --------------------------------------- ---------------------------------- Reason for the notification 2 --------------------------------------------------------------------------- a) Position/status Chief Executive Officer --------------------------------------- ---------------------------------- b) Initial notification Initial notification /Amendment --------------------------------------- ---------------------------------- Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor --------------------------------------------------------------------------- a) Name Yourgene Health plc --------------------------------------- ---------------------------------- b) LEI 213800UUIT8BZE7QEH33 --------------------------------------- ---------------------------------- Details of the transaction(s): section to be repeated 4 for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --------------------------------------------------------------------------- a) Description of the Ordinary shares of 0.1p each financial instrument, type of instrument Identification code ISIN: GB00BN31ZD89 b) Nature of the transaction Purchase of ordinary shares --------------------------------------- ---------------------------------- c) Price(s) and volume(s) -------------- --------------- Price(s) Volume(s) -------------- --------------- 7.1p 1,000,000 -------------- --------------- d) Aggregated information N/A - Aggregated volume - Price e) Date of the transaction 11 May 2022 --------------------------------------- ---------------------------------- f) Place of the transaction UK --------------------------------------- ----------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFZGMKNMLGZZM
(END) Dow Jones Newswires
May 12, 2022 02:02 ET (06:02 GMT)
1 Year Yourgene Health Chart |
1 Month Yourgene Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions